Drug Profile


Alternative Names: ATI-5000; ATI-5923

Latest Information Update: 14 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ARYx Therapeutics
  • Developer Espero BioPharma
  • Class Anticoagulants; Small molecules
  • Mechanism of Action Vitamin K epoxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Thromboembolism; Thrombosis

Most Recent Events

  • 30 Mar 2017 Armetheon announces intention to submit NDA to US FDA in the year 2019
  • 14 Feb 2017 Phase-III clinical trials in Thrombosis (Prevention) in USA (PO) before February 2017 (Armetheon Pipeline, February 2017)
  • 14 Feb 2017 The European Medicines Agency Scientific Advice Working Group advises that Armetheon conduct a pivotal phase III trial for Thromboembolism and Thrombosis (Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top